 | |
| | Introduction |
| | |
Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
Karen L. Bell, M.D. |
| | | Treatment Strategies for Dementia and Mild Cognitive Impairment
Mary Sano, Ph.D. |
| | | Treatment of Depression, Agitation, and Psychosis in Dementia
Davangere P. Devanand, M.D. |
|
| | Recognition of Vascular Dementia, Dementia with Lewy Bodies, and Frontotemporal Dementia
Lawrence S. Honig, M.D., Ph.D. |
|
| |
Neuropsychology of Mild Cognitive Impairment, Alzheimer's Disease, Dementia with Lewy Bodies, and Frontotemporal Dementia
Penne Sims, Ph.D. |
|
| |
Neuroimaging in Dementia
Scott A. Small, M.D. |
|
| |
Genetics of Neurodegenerative Disease: Alzheimer's Disease, Frontotemporal Dementia
Jennifer Williamson-Catania, M.S. |
|
| |
Legal and Ethical Issues for Patients with Dementia
Daniel G. Fish, Esq. |
|
|
Posttest
|
|
|
|
|
|
Accreditation
|
|
| Reference List
|
|
| Acknowledgements
|
|
|
| | | |
Acknowledgements
|
|
This course was produced by Columbia University Digital Knowledge Ventures (DKV) at Columbia University in collaboration with the Columbia University College of Physicians and Surgeons, Taub Institute for Research on Alzheimer's Disease and the Aging Brain, and the Department of Neurology, Division of Aging and Dementia. Columbia DKV fosters the global exchange of information and ideas through the creation of innovative digital learning resources.
Thank you to the many people and organizations that provided this course with material or support.
This program is supported by an educational grant from
Janssen Pharmaceutica Inc. and Ortho-McNeil Pharmaceutical, Inc.
This activity was sponsored by Education and Information Transfer Core of the Columbia University Alzheimer's Disease Research Center (through National Institutes of Health Grant AG-08702).
|
|
Taub Institute
|
|
| The Taub Institute for Research on Alzheimer's Disease and the Aging Brain is an interdisciplinary institute in Columbia University's College of Physicians and Surgeons. Its mission is to develop the means to identify vulnerable individuals at risk for Alzheimer's disease and devise new therapies to prevent or delay disorders of the aging brain.
|
|
|
